Treatment of Myoclonic Jerks
The treatment of myoclonic jerks should be targeted based on the underlying cause, with valproate, levetiracetam, and piracetam being first-line treatments for cortical myoclonus, while clonazepam is the first-line treatment for subcortical/brainstem myoclonus. 1, 2
Diagnostic Approach to Myoclonic Jerks
Before initiating treatment, proper characterization of myoclonus is essential:
- Determine timing of myoclonus: At rest, during posture maintenance, or with action
- Distribution pattern: Focal, multifocal, or generalized
- Stimulus sensitivity: Whether jerks are triggered by specific stimuli
- Associated features: Presence of other neurological symptoms or signs
EEG is crucial for differentiating epileptic from non-epileptic myoclonus and can help classify the type of myoclonus (cortical, subcortical, or spinal) 1.
Treatment Algorithm Based on Myoclonus Type
1. Cortical Myoclonus
- First-line treatments:
- Valproate (most effective for epileptic myoclonus)
- Levetiracetam (shown to be effective in 60.4% of patients with juvenile myoclonic epilepsy) 3
- Piracetam
2. Subcortical/Brainstem Myoclonus
3. Focal or Segmental Myoclonus
4. Post-anoxic Myoclonus (Lance-Adams Syndrome)
- First-line treatment:
- Levetiracetam 1
- Alternative options:
- Valproate
- Clonazepam
Special Considerations
Combination therapy: Single agents rarely control myoclonus completely; polytherapy with a combination of drugs is often needed 2
Medication warnings:
Refractory cases:
- Consider deep brain stimulation targeting the globus pallidus pars-interna bilaterally when pharmacological treatments have failed 1
Acute management:
Underlying causes: Always investigate and treat underlying causes, such as:
Monitoring and Follow-up
- Continuous EEG should be considered in patients with diagnosed status epilepticus 1
- Regular follow-up to assess treatment efficacy and side effects
- Adjust medication doses as needed, often requiring higher doses than standard anticonvulsant therapy
The prognosis for myoclonus varies significantly based on the underlying cause. For conditions like Lance-Adams syndrome, 85% of patients show improvement over time, with approximately 77% achieving symptomatic control at a median of 70 days 1.